Abergel, Armand

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 642

Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin

Ruivard, M., Lainé, F., Ganz, T., Olbina, G., Westerman, M., Nemeth, E., Rambeau, M., Mazur, A., Gerbaud, L., Tournilhac, V., et al. (2009) · Journal of Hepatology

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 89

A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

Corpechot, C., Chazouillères, O., Rousseau, A., Guyader, D., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 45